Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Peritoneal contamination with ICG-stained cervical secretion as surrogate for potential cervical cancer tumor cell dissemination: A proof-of-principle study for laparoscopic hysterectomy.

Klapdor R, Hertel H, Hillemanns P, Röttger M, Soergel P, Kuehnle E, Jentschke M.

Acta Obstet Gynecol Scand. 2019 Nov;98(11):1398-1403. doi: 10.1111/aogs.13681. Epub 2019 Jul 23.

PMID:
31242322
2.

Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study.

Klapdor R, Wölber L, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N, Hillemanns P, Fürst ST, Mahner S.

Gynecol Oncol. 2019 Sep;154(3):565-570. doi: 10.1016/j.ygyno.2019.06.013. Epub 2019 Jun 18.

PMID:
31227222
3.

Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.

Klapdor R, Wang S, Morgan M, Dörk T, Hacker U, Hillemanns P, Büning H, Schambach A.

Int J Mol Sci. 2019 Feb 3;20(3). pii: E660. doi: 10.3390/ijms20030660.

4.

Should we really abandon inguinal lymphadenectomy in the treatment of vulvar cancer?

Klapdor R, Hillemanns P.

Acta Obstet Gynecol Scand. 2019 Mar;98(3):399. doi: 10.1111/aogs.13497. Epub 2018 Nov 15. No abstract available.

PMID:
30367452
5.

Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetium-99m-nanocolloid.

Soergel P, Kirschke J, Klapdor R, Derlin T, Hillemanns P, Hertel H.

Lasers Surg Med. 2018 Dec;50(10):994-1001. doi: 10.1002/lsm.22999. Epub 2018 Jul 3.

PMID:
29968916
6.

The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias.

Friebe K, Klapdor R, Hillemanns P, Jentschke M.

Geburtshilfe Frauenheilkd. 2017 Aug;77(8):887-893. doi: 10.1055/s-0043-115395. Epub 2017 Aug 24.

7.

Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.

Klapdor R, Wang S, Hacker U, Büning H, Morgan M, Dörk T, Hillemanns P, Schambach A.

Hum Gene Ther. 2017 Oct;28(10):886-896. doi: 10.1089/hum.2017.168. Epub 2017 Aug 24.

PMID:
28836469
8.

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.

Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P, Etter JL, Cramer DW, Diergaarde B, Doherty JA, Dörk T, Edwards R, deFazio A, Friel G, Goodman MT, Hillemanns P, Høgdall E, Jensen A, Jordan SJ, Karlan BY, Kjær SK, Klapdor R, Matsuo K, Mizuno M, Nagle CM, Odunsi K, Paddock L, Rossing MA, Schildkraut JM, Schmalfeldt B, Segal BH, Starbuck K, Terry KL, Webb PM, Zsiros E, Ness RB, Modugno F, Bandera EV, Chang-Claude J, Moysich KB.

Br J Cancer. 2017 Sep 26;117(7):1063-1069. doi: 10.1038/bjc.2017.267. Epub 2017 Aug 17.

9.

Sentinel Lymphadenectomy in Vulvar Cancer Using Near-Infrared Fluorescence From Indocyanine Green Compared With Technetium 99m Nanocolloid.

Soergel P, Hertel H, Nacke AK, Klapdor R, Derlin T, Hillemanns P.

Int J Gynecol Cancer. 2017 May;27(4):805-812. doi: 10.1097/IGC.0000000000000996.

PMID:
28399034
10.

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.

Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, Odunsi K, Mayor P, Zsiros E, Schmalfeldt B, Klapdor R, Dӧrk T, Hillemanns P, Kelemen LE, Kӧbel M, Steed H, de Fazio A; Australian Ovarian Cancer Study Group, Jordan SJ, Nagle CM, Risch HA, Rossing MA, Doherty JA, Goodman MT, Edwards R, Matsuo K, Mizuno M, Karlan BY, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LF, Kupryjanczyk J, Berchuck A, Chang-Claude J, Diergaarde B, Webb PM, Moysich KB; Ovarian Cancer Association Consortium.

Cancer Causes Control. 2017 May;28(5):469-486. doi: 10.1007/s10552-017-0867-1. Epub 2017 Mar 14.

11.

Association between intraabdominal pressure during gynaecologic laparoscopy and postoperative pain.

Kundu S, Weiss C, Hertel H, Hillemanns P, Klapdor R, Soergel P.

Arch Gynecol Obstet. 2017 May;295(5):1191-1199. doi: 10.1007/s00404-017-4325-9. Epub 2017 Mar 11.

PMID:
28285427
12.

Postoperative anatomic and quality-of-life outcomes after vaginal sacrocolporectopexy for vaginal vault prolapse.

Klapdor R, Grosse J, Hertel B, Hillemanns P, Hertel H.

Int J Gynaecol Obstet. 2017 Apr;137(1):86-91. doi: 10.1002/ijgo.12095. Epub 2017 Feb 2.

PMID:
28099751
13.

Application of sentinel lymph node dissection in gynecological cancers: results of a survey among German hospitals.

Klapdor R, Hertel H, Soergel P, Jentschke M, Hillemanns P.

Arch Gynecol Obstet. 2017 Mar;295(3):713-720. doi: 10.1007/s00404-016-4279-3. Epub 2016 Dec 29.

PMID:
28035487
14.

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study.

Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S.

Ann Surg Oncol. 2017 May;24(5):1314-1321. doi: 10.1245/s10434-016-5687-0. Epub 2016 Nov 28.

PMID:
27896515
15.

Groin Recurrences in Node Negative Vulvar Cancer Patients After Sole Sentinel Lymph Node Dissection.

Klapdor R, Hertel H, Soergel P, Hillemanns P.

Int J Gynecol Cancer. 2017 Jan;27(1):166-170. doi: 10.1097/IGC.0000000000000860.

PMID:
27870709
16.

Photodynamic diagnosis with 5-aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study.

Hillemanns P, Wimberger P, Reif J, Stepp H, Klapdor R.

Lasers Surg Med. 2017 Feb;49(2):169-176. doi: 10.1002/lsm.22613. Epub 2016 Nov 16.

PMID:
27859395
17.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

18.

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.

Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, Kelemen LE, Goodman MT, Bandera EV, Terry KL, Schoof N, Eng KH, Clay A, Singh PK, Joseph JM, Aben KK, Anton-Culver H, Antonenkova N, Baker H, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Despierre E, Dicks E, Doherty JA, du Bois A, Dürst M, Easton D, Eccles D, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hogdall C, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kelley JL, Kiemeney LA, Klapdor R, Kolomeyevskaya N, Krakstad C, Kjaer SK, Kruszka B, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Liu S, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Moes-Sosnowska J, Narod SA, Nedergaard L, Nevanlinna H, Nickels S, Olson SH, Orlow I, Weber RP, Paul J, Pejovic T, Pelttari LM, Perkins B, Permuth-Wey J, Pike MC, Plisiecka-Halasa J, Poole EM, Risch HA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schmitt K, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Tangen IL, Teo SH, Thompson PJ, Timorek A, Tsai YY, Tworoger SS, Tyrer J, van Altena AM, Vergote I, Vierkant RA, Walsh C, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Gayther SA, Ramus SJ, Sellers TA, Schildkraut JM, Phelan CM, Berchuck A, Chenevix-Trench G, Cunningham JM, Pharoah PP, Ness RB, Odunsi K, Goode EL, Moysich KB.

Oncotarget. 2016 Oct 25;7(43):69097-69110. doi: 10.18632/oncotarget.10215.

19.

Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.

Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB.

Br J Cancer. 2016 Jun 28;115(1):95-101. doi: 10.1038/bjc.2016.153. Epub 2016 Jun 14.

20.

Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.

Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Brian Szender J, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva AN, Zirpoli GR, Bandera EV, Berchuck A, Cramer D, Doherty JA, Edwards RP, Fridley BL, Goode EL, Goodman MT, Hogdall E, Hosono S, Jensen A, Jordan S; Australian Ovarian Cancer Study Group, Kjaer SK, Matsuo K, Ness RB, Olsen CM, Olson SH, Leigh Pearce C, Pike MC, Anne Rossing M, Szamreta EA, Thompson PJ, Tseng CC, Vierkant RA, Webb PM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Schildkraut JM, Terry KL, Kelemen LE, Moysich KB.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1114-24. doi: 10.1158/1055-9965.EPI-15-1330. Epub 2016 May 6. Review.

21.

Rare ATAD5 missense variants in breast and ovarian cancer patients.

Maleva Kostovska I, Wang J, Bogdanova N, Schürmann P, Bhuju S, Geffers R, Dürst M, Liebrich C, Klapdor R, Christiansen H, Park-Simon TW, Hillemanns P, Plaseska-Karanfilska D, Dörk T.

Cancer Lett. 2016 Jun 28;376(1):173-7. doi: 10.1016/j.canlet.2016.03.048. Epub 2016 Apr 1.

PMID:
27045477
22.

Treatment of Giant Fibroadenoma in Young Women: Results after Tumor Excision without Reconstructive Surgery.

Hille-Betz U, Klapdor R, Henseler H, Soergel P, Länger F.

Geburtshilfe Frauenheilkd. 2015 Sep;75(9):929-934.

23.

Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy : Risk-modifying factors.

Hille-Betz U, Vaske B, Bremer M, Soergel P, Kundu S, Klapdor R, Hillemanns P, Henkenberens C.

Strahlenther Onkol. 2016 Jan;192(1):8-16. doi: 10.1007/s00066-015-0899-y. Epub 2015 Sep 28.

PMID:
26416291
24.

Radiofrequency endometrial ablation for the treatment of heavy menstrual bleeding among women at high surgical risk.

Fischer F, Klapdor R, Gruessner S, Ziert Y, Hillemanns P, Hertel H.

Int J Gynaecol Obstet. 2015 Nov;131(2):123-8. doi: 10.1016/j.ijgo.2015.05.028. Epub 2015 Aug 16.

PMID:
26337815
25.

SPECT/CT for SLN dissection in vulvar cancer: Improved SLN detection and dissection by preoperative three-dimensional anatomical localisation.

Klapdor R, Länger F, Gratz KF, Hillemanns P, Hertel H.

Gynecol Oncol. 2015 Sep;138(3):590-6. doi: 10.1016/j.ygyno.2015.06.011. Epub 2015 Jun 9.

PMID:
26067332
26.

Breast reconstruction and revision surgery for implant-associated breast deformities using porcine acellular dermal matrix: a multicenter study of 156 cases.

Hille-Betz U, Kniebusch N, Wojcinski S, Henseler H, Heyl V, Ohlinger R, Paepke S, Klapdor R, Krause-Bergmann B.

Ann Surg Oncol. 2015 Apr;22(4):1146-52. doi: 10.1245/s10434-014-4098-3. Epub 2014 Oct 10.

PMID:
25300607
27.

Isthmocervical labelling and SPECT/CT for optimized sentinel detection in endometrial cancer: technique, experience and results.

Mücke J, Klapdor R, Schneider M, Länger F, Gratz KF, Hillemanns P, Hertel H.

Gynecol Oncol. 2014 Aug;134(2):287-92. doi: 10.1016/j.ygyno.2014.05.001. Epub 2014 May 10.

PMID:
24823647
28.

Value and advantages of preoperative sentinel lymph node imaging with SPECT/CT in cervical cancer.

Klapdor R, Mücke J, Schneider M, Länger F, Gratz KF, Hillemanns P, Hertel H.

Int J Gynecol Cancer. 2014 Feb;24(2):295-302. doi: 10.1097/IGC.0000000000000032.

PMID:
24401983
29.

Evaluation of active camera control systems in gynecological surgery: construction, handling, comfort, surgeries and results.

Beckmeier L, Klapdor R, Soergel P, Kundu S, Hillemanns P, Hertel H.

Arch Gynecol Obstet. 2014 Feb;289(2):341-8. doi: 10.1007/s00404-013-3004-8.

PMID:
23959091
30.

European proficiency study with control serum for the tumor marker CA 19-9 measured on different test systems.

Bertsch T, Aschenneller C, Bewarder N, Beyrau R, Herrmann BL, Jansen E, Klapdor R, Klemm M, Meissner J, Pfeiffer S, Schauer I, Stratmann MM, Theimer C, van de Loo HM, Wildbredt DA, Wolff C, Wollenberg P.

Clin Lab. 2013;59(1-2):185-92.

PMID:
23505925
32.
33.
34.

Alpha-1-Fetoprotein (AFP): international proficiency study with different test systems.

Oremek GM, Oertl A, Bertsch T, Bewarder N, Bürger V, Dannenberg R, Dibbelt L, Gerstmeyer A, Grunow G, Irmer-Vorpeil A, Klapdor R, Klemm M, Krengel G, Lerahn A, Marivoet S, Misianik J, Ortin V, Peeters V, Röder B, Schauer I, Schneider A, Schweiger AM, Seefried D, Straetmans D, Trommer A, Weinhold A.

Clin Lab. 2011;57(9-10):669-75.

PMID:
22029181
35.
36.

Vascular endothelial growth factor (VEGF) in sera of oral and oropharyngeal squamous cell carcinoma patients.

Friedrich RE, Klapdor R, Hagel C, Bartel-Friedrich S.

Anticancer Res. 2010 May;30(5):1765-6.

PMID:
20592375
37.

Immunohistochemical study on an epithelial-myoepithelial intercalated duct carcinoma transplanted to the nude mouse.

Friedrich RE, Klapdor R, Hagel C, Bartel-Friedrich S.

Anticancer Res. 2010 May;30(5):1565-8.

PMID:
20592342
38.

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V.

Ann Oncol. 2010 Mar;21(3):441-7. doi: 10.1093/annonc/mdp332. Epub 2009 Aug 18. Review.

PMID:
19690057
39.

Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.

Friedrich RE, Klapdor R, Bartel-Friedrich S.

Anticancer Res. 2007 Jul-Aug;27(4A):2099-100.

40.

Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer.

Klapdor R, Bahlo M, Babinsky A, Brenzinger ML.

Anticancer Res. 2007 Jul-Aug;27(4A):1789-94.

41.

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O.

Eur J Cancer. 2007 Jun;43(9):1348-60. Epub 2007 May 18. Review.

PMID:
17512720
42.

A multi-center quality control study of different CA15-3 immunoassays.

Hubl W, Demant T, Albrecht S, Bewarder N, Grunow G, Keller R, Klapdor R, Klos KJ, Kruse K, Müller R, Päge I, Schmidt R, Stolle H, Wiefelspütz J, vom Baur E, Zinsmeyer J, Zwirner M.

Clin Lab. 2005;51(11-12):641-5.

PMID:
16329622
44.

Atypical courses of serum tumor markers--4 case reports.

Klapdor R, Bahlo M, Babinski A.

Anticancer Res. 2003 Mar-Apr;23(2A):845-50.

PMID:
12820311
45.

Sequential polychemotherapy in exocrine pancreatic cancer.

Klapdor R, Bahlo M, Babinski A, Broemel T, Müller C, Seutter R.

Anticancer Res. 2003 Mar-Apr;23(2A):841-4.

PMID:
12820310
46.

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.

Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O.

Eur J Cancer. 2003 Apr;39(6):718-27. Review.

PMID:
12651195
47.

Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer.

Klapdor R, Fenner C.

Anticancer Res. 2000 Nov-Dec;20(6D):5209-12.

PMID:
11326696
48.

Improvement of survival by efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer.

Klapdor R, Müller C, Seutter R, Bahlo M, Peters W, Fenner C.

Anticancer Res. 2000 Nov-Dec;20(6D):5201-7.

PMID:
11326695
49.

Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.

Halm U, Rohde N, Klapdor R, Reith HB, Thiede A, Etzrodt G, Mössner J, Keller T.

Anticancer Res. 2000 Nov-Dec;20(6D):4957-60.

PMID:
11326646
50.

Tumor marker determination after orthotopic heart transplantation.

Nägele H, Bahlo M, Klapdor R, Rödiger W.

J Heart Lung Transplant. 1999 Oct;18(10):957-62.

PMID:
10561106

Supplemental Content

Loading ...
Support Center